Novo Nordisk’s Q4 2026 earnings beat driven by Wegovy pill demand
Resolves: Novo Nordisk’s Q4 2026 earnings report shows revenue from Wegovy (oral) exceeding analyst consensus estimates by at least 10%.
user-generated· earnings
Novo Nordisk’s Q4 2026 earnings beat driven by Wegovy pill demand
Market overview
Novo Nordisk’s oral Wegovy sales will outpace expectations, contributing significantly to Q4 2026 revenue growth. Oral formulations are expected to cannibalize a portion of injectable sales but drive overall market expansion.
earnings prediction market
- Implied probability (Yes)
- 65%
- Closes
- 2027-01-31
About this prediction
Resolution criteria
Novo Nordisk’s Q4 2026 earnings report shows revenue from Wegovy (oral) exceeding analyst consensus estimates by at least 10%.
Source: user-generated
More earnings markets
- Will cash burn exceed $5M in Q4? — 65% Yes
- Will Venyra beat Q4 2026 revenue consensus of $230M? — 85% Yes
- Will Nuburu secure emergency financing by Q3 end? — 35% Yes
- Will Everpure, Inc. report a non-GAAP EPS beat for the quarter ended June 30, 2026? — 50% Yes
- Will KR miss Q4 operating margin guidance? — 65% Yes
- Will George Risk report Q4 2026 revenue above $13M? — 85% Yes
- Will DCI beat Q4 EPS consensus of $0.88? — 65% Yes
- Will inventory days decrease below 70 by year-end? — 40% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…